Results 81 to 90 of about 17,596,944 (314)
Methylation biomarkers can distinguish pleural mesothelioma from healthy pleura and other pleural pathologies
Molecular Oncology, EarlyView.We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy. Janah Vandenhoeck, Nele De Meulenaere, Thomas Vanpoucke, Joe Ibrahim, Dieter Peeters, Suresh Krishan Yogeswaran, Wen Wen, Paul Van Schil, Jeroen M. H. Hendriks, Jo Raskin, Jan van Meerbeeck, Guy Van Camp, Ken Op de Beeck +12 morewiley +1 more sourcePerspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology
Molecular Oncology, EarlyView.Liquid biopsy enables minimally invasive, real‐time molecular profiling through analysis of circulating biomarkers in biological fluids. This Perspective highlights the importance of training pathologists through integrative educational programs, such as the European Masters in Molecular Pathology, to ensure effective and equitable implementation of ...Marius Ilié, Umberto Malapelle, Catherine Alix‐Panabières, Claus Lindbjerg Andersen, Sandra Chlebowski, Vivien Lake, Caroline Lacoux, Virginie Lespinet‐Fabre, Olivier Bordone, Simon Heeke, Christophe Bontoux, Ellen Heitzer, Klaus Pantel, Paul Hofman +13 morewiley +1 more sourceNumerical Approaches to Spacetime Singularities [PDF]
, 2002 This Living Review updates a previous version which its itself an update of a
review article. Numerical exploration of the properties of singularities could,
in principle, yield detailed understanding of their nature in physically
realistic cases ...A A Kirillov, A A Kirillov, A A Moser, A Ashtekar, A B Burd, A Bonanno, A D Rendall, A D Rendall, A D Rendall, A E Motter, A H Norton, A M Abrahams, A M Abrahams, A Ori, A Ori, A Ori, A Ori, A Ori, A P Gentle, A Taub, A Zardecki, B Grubišić, B Grubišić, B Grubišić, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, B K Berger, C Barrabès, C Gundlach, C Gundlach, C Gundlach, C Gundlach, C Gundlach, C Gundlach, C M Chambers, C M Chambers, C M Chambers, C R Evans, C W Misner, D Christodoulou, D Christodoulou, D Eardley, D Eardley, D F Chernoff, D Garfinkle, D Garfinkle, D Garfinkle, D Garfinkle, D Garfinkle, D Garfinkle, D Garfinkle, D Garfinkle, D Garfinkle, D M Eardley, D Maison, D R Brill, D S Goldwirth, D V Gal’tsov, D V Gal’tsov, D W Hobill, E E Donets, E Kasner, E Poisson, E Poisson, E Poisson, E Seidel, E W Hirschmann, E W Hirschmann, E W Hirschmann, F Echeverria, F J Tipler, F Mellor, F Mellor, F Pretorius, G F R Ellis, G Francisco, G Johnson, G Montani, G Rein, H Elst van, H Friedrich, H Iguchi, H Iguchi, H Iguchi, H Ringström, H Ringström, I M Khalatnikov, I Olabarrieta, J A Fleck, J A Isenberg, J C Niemeyer, J D Barrow, J D Barrow, J Isenberg, J Libson, J Masso, J Pullin, J Wojtkiewicz, J Yokoyama, K Ferraz, K Nakao, K P Tod, K S Thorne, L Andersson, L M Burko, L M Burko, L M Burko, L M Burko, L M Burko, L M Burko, L S Finn, M A Pelath, M Bañados, M H P M Putten van, M L Gnedin, M MacCallum, M P Ryan Jr., M P Ryan Jr., M Suzuki, M Suzuki, M W Browne, M W Choptuik, M W Choptuik, M Weaver, M Weaver, M Weaver, M Weaver, N Deruelle, N J Cornish, N J Cornish, O Iguchi, P Anninos, P Anninos, P Bizoń, P Bizoń, P Bizoń, P Bizoń, P Breitenlohner, P Breitenlohner, P Breitenlohner, P Halpern, P Hübner, P Hübner, P K-H Ma, P R Brady, P R Brady, P R Brady, P R Brady, P R Brady, P R Brady, P T Chrusciel, P T Chruściel, R Bartnik, R Carretero-Gonzalez, R H Gowdy, R M Wald, R M Wald, R Ove, R Penrose, R Penrose, R S Hamadé, R S Hamadé, R Schoen, R T Jantzen, R T Jantzen, S A Teukolsky, S Chandrasekhar, S Cotsakis, S D Hern, S Droz, S E Rugh, S E Rugh, S E Rugh, S Hod, S Hod, S Hod, S Hod, S Hod, S Husa, S J Hern, S Kichenassamy, S L Liebling, S L Shapiro, S L Shapiro, S L Shapiro, S M C V Gonçalves, S W Hawking, S W Hawking, S W Hawking, T Chiba, T Chiba, T Damour, T Damour, T Harada, T Harada, T Koike, T Nakamura, T Nakamura, T Nakamura, V A Belinskii, V A Belinskii, V A Belinskii, V A Belinskii, V A Belinskii, V A Belinskii, V A Belinskii, V G LeBlanc, V G LeBlanc, V Moncrief, V Moncrief, V Moncrief, V Moncrief, W H Press, W Israel, W Israel, Z B Belanger +232 morecore +3 more sourcesMonitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer
Molecular Oncology, EarlyView.Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien +35 morewiley +1 more sourceDeveloping evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking +43 morewiley +1 more sourceLDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro
Molecular Oncology, EarlyView.Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber +13 morewiley +1 more source
